Published in Lung Cancer on September 01, 2003
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95
Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol (2010) 2.26
MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol (2009) 1.13
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol (2009) 1.09
Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. Int J Pharm (2010) 1.07
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2010) 0.95
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol (2009) 0.94
Personalizing therapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med (2013) 0.89
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer (2007) 0.88
Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer. Br J Cancer (2004) 0.87
Management of non-small cell lung cancer with oligometastasis. Curr Oncol Rep (2012) 0.83
Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. Int J Clin Oncol (2010) 0.82
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy. BMC Gastroenterol (2014) 0.81
Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC). J Thorac Dis (2011) 0.80
The role of anti-angiogenesis in non-small-cell lung cancer: an update. Curr Oncol Rep (2015) 0.79
A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers. Arch Med Sci (2014) 0.79
A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer. Oncotarget (2015) 0.79
Personalized therapy for non-small cell lung cancer: which drug for which patient? Semin Thorac Cardiovasc Surg (2011) 0.78
A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients. Chemotherapy (2012) 0.78
Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy. J Adv Pract Oncol (2012) 0.77
Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study. Cancer Med (2014) 0.76
Afatinib treatment in advanced non-small cell lung cancer. Lung Cancer (Auckl) (2011) 0.75
Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer. Int J Clin Oncol (2012) 0.75
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study. Int J Hematol (2017) 0.75
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol (2007) 4.94
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol (2010) 3.88
Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer (2004) 2.38
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol (2007) 2.16
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol (2008) 1.92
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst (2013) 1.28
Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2002) 1.22
High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res (2005) 1.19
Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest (2007) 1.07
Adenocarcinoma of the lung among women: risk associated with smoking, prior lung disease, diet and menstrual and pregnancy history. Lung Cancer (2003) 1.06
Presentation, management and outcome of 32 patients with pregnancy-associated breast cancer: a matched controlled study. Breast J (2009) 1.05
Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. Anticancer Res (2010) 0.96
Prognostic significance of TIMP-1 in non-small cell lung cancer. Anticancer Res (2011) 0.93
The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Genet (2013) 0.90
The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. Breast Cancer Res Treat (2005) 0.88
Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy. Anticancer Res (2013) 0.88
Lung cancer risk among Czech women: a case-control study. Prev Med (2002) 0.87
Breast cancer risk assessment in the Czech female population--an adjustment of the original Gail model. Breast Cancer Res Treat (2005) 0.86
Gemcitabine/carboplatin in advanced non-small cell lung cancer. Lung Cancer (2002) 0.85
Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study. Expert Opin Pharmacother (2003) 0.85
Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. Anticancer Res (2012) 0.85
Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. Cancer (2011) 0.83
Diagnostic and prognostic significance of inflammatory markers in lung cancer-associated pleural effusions. Int J Biol Markers (2010) 0.82
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. Breast Cancer Res Treat (2013) 0.82
Progelatinase B/matrix metalloproteinase-9 proenzyme as a marker of pleural inflammation. Exp Lung Res (2004) 0.82
KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res (2005) 0.81
[Cancer multiplicities in the Czech population]. Cas Lek Cesk (2010) 0.81
Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation. Tumour Biol (2015) 0.81
Vitamin D in colorectal, breast, prostate and lung cancer: a pilot study. Anticancer Res (2011) 0.80
4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study. Bull Cancer (2004) 0.80
Levels of cathepsins S and H in pleural fluids of inflammatory and neoplastic origin. Int J Biol Markers (2009) 0.78
A novel high-resolution chipCE assay for rapid detection of EGFR gene mutations and amplifications in lung cancer therapy by a combination of fragment analysis, denaturing CE and MLPA. Electrophoresis (2010) 0.78
Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma. Support Care Cancer (2005) 0.77
Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. Anticancer Res (2013) 0.77
Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence. Anticancer Res (2013) 0.76
Therapy of small cell lung cancer with emphasis on oral topotecan. Lung Cancer (2010) 0.75
[Oxidative stress after anthracycline therapy in patients with solid tumors]. Cas Lek Cesk (2012) 0.75
A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. Clin Cancer Res (2006) 0.75
[In Process Citation]. Klin Onkol (2015) 0.75
Towards a regional network of respiratory medicine. Pneumologia (2016) 0.75
Highlights from the 7th central European lung cancer conference. Lung Cancer (2002) 0.75
Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy. J Sep Sci (2010) 0.75
Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report. Tumori (2014) 0.75
[News from the 13th European Cancer Conference (ECCO-13)]. Cas Lek Cesk (2006) 0.75
[Principal value of surgical therapy in the renal cell cancer, chances of the biological treatment]. Cas Lek Cesk (2011) 0.75
Assessment of in vitro drug resistance of human breast cancer cells subcultured from biopsy specimens. Anticancer Res (2003) 0.75
Breast cancer characteristics-comparison of preoperative and postoperative values. Pathol Res Pract (2013) 0.75